PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Neurovirol. Author manuscript; available in PMC Dec 30, 2012.
Published in final edited form as:
PMCID: PMC3299008
NIHMSID: NIHMS353224
The herpes simplex virus type 1 latency associated transcript locus is required for the maintenance of reactivation competent latent infections
Richard L. Thompson and Nancy M. Sawtell
Richard L. Thompson, Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, 45267-0524, USA;
Contact: Corresponding Author: Richard L. Thompson ; Richard.Thompson/at/uc.edu 513-558-0063 Phone 513-558-8474 FAX
Herpes simplex virus type (HSV) infects and replicates at the body surface and establishes latent infections in innervating sensory neurons. Stressful stimuli can cause reactivation of the latent virus and recurrent disease, which facilitates infection of new hosts (Knipe and Howley 2007). While most reactivation events are asymptomatic, recurrence in the eye is a leading cause of blindness (Pepose, Keadle et al. 2006; Toma, Murina et al. 2008), and reactivation of HSV in the genital tract is associated with a three fold higher transmission rate of HIV (Glynn, Biraro et al. 2009; Fuchs, Celum et al. 2010). In addition, rare but serious sequelae including fatal encephalitis can occur (Stone and Hawkins 2007). In experimental models the frequency of reactivation is directly correlated with the level of latent infections (Sawtell 1998; Sawtell, Poon et al. 1998; Sawtell 2003), but factors that influence the establishment and maintenance of latent infections are not well understood.
In our mouse model about 6000 neurons per TG are latently infected as defined by the presence of the viral genome (Sawtell 1997; Thompson and Sawtell 1997; Sawtell, Poon et al. 1998; Thompson and Sawtell 2001). Spontaneous reactivation occurs in one neuron out of 20 TG or about 1/120,000 latently infected neurons per day (Sawtell 1998). Stressful stimuli including hyperthermic stress (HS) increase the reactivation frequency about 50-fold, to ~1/2500 (Sawtell 1998; Sawtell, Poon et al. 1998; Thompson, Preston et al. 2009). Clearly the maintenance of latent infections is tightly controlled, but little is known about viral functions that maintain the latent state.
The latency associated transcript (LAT) locus has been extensively investigated. and shown to express several unusual forms of non-coding RNAs during latency including a primary transcript, stable introns spliced from this transcript, small RNAs and microRNAs, one of which is upstream of the LAT promoter and encoded on the opposite strand (Rock, Nesburn et al. 1987; Stevens, Wagner et al. 1987; Wechsler, Nesburn et al. 1988; Farrell, Dobson et al. 1991; Peng, Vitvitskaia et al. 2008; Umbach, Kramer et al. 2008). In addition, some evidence of viral proteins expressed during latency (most from the LAT region) has been reported (Green, Courtney et al. 1981; Doerig, Pizer et al. 1991; Thomas, Gough et al. 1999; Perng, Maguen et al. 2002; Thomas, Lilley et al. 2002; Henderson, Jaber et al. 2009; Jaber, Henderson et al. 2009), but the functions of these proteins are not known.
We and others have shown that HSV-1 LAT mutants can establish latent infections and reactivate from them (Sedarati, Izumi et al. 1989; Sawtell and Thompson 1992; Bloom, Devi-Rao et al. 1994; Perng, Dunkel et al. 1994; Thompson and Sawtell 1997; Thompson and Sawtell 2001) . Analysis at the single neuron level reveals that significantly fewer latent infections are established by LAT null mutants demonstrating a role for this locus during the establishment of latency (Sawtell and Thompson 1992; Thompson and Sawtell 1997; Perng, Slanina et al. 2000; Thompson and Sawtell 2001). In the mouse model this is likely to be due to a function which serves to suppress lytic viral protein production in TG neurons (Sawtell and Thompson 1992; Garber, Schaffer et al. 1997; Thompson and Sawtell 1997). In the absence of the LAT locus significantly more neurons expressing the LAT promoter enter into lytic infection and fewer neurons survive (Sawtell and Thompson 1992; Thompson and Sawtell 1997; Thompson and Sawtell 2001).
The LAT locus is expressed in a subset of neurons during latency (Deatly, Spivack et al. 1987; Rock, Nesburn et al. 1987; Stevens, Wagner et al. 1987; Arthur, Efstathiou et al. 1993). We hypothesize that regulators encoded in the LAT locus provide function(s) that repress entry into the lytic cycle and this in turn serves to moderate the frequency of reactivation and maintains the pool of latently infected neurons through time (Sawtell and Thompson 1992; Garber, Schaffer et al. 1997; Thompson and Sawtell 1997; Thompson and Sawtell 2001; Kang, Mukerjee et al. 2003). For example, there is a post transcriptional constraint on the production of ICP0 mediated by the LAT locus during in vivo reactivation (Thompson, Shieh et al. 2003). In this way the frequency of reactivation and or the number of neurons exiting latency per reactivation event could be limited. This would be important to minimize loss from the pool of latently infected neurons which, in turn, would increase the probability of transmission to new hosts throughout the life of the infected individual. If this hypothesis is true, then reactivation competent latent infections established by LAT null viruses should be more prone to reactivate than those established by viruses that have an intact LAT locus.
In previous experiments with 17syn+, we found that the frequency of reactivation is not significantly reduced during long term latency (spanning >250 days) (Sawtell 2003). In addition, preliminary experiments revealed that when mice latently infected with 17syn+ were induced to reactivate multiple times over a 5 month period using hyperthermic stress (HS), a physiologically relevant stress that induces reactivation from latency in vivo (Sawtell and Thompson 1992), that the final reactivation frequency was not different from that after a single HS (66% vs 68% respectively). This information and experimental set up was used to directly test whether reactivation competent latent infections established by the LAT null mutant 17AH would be depleted over time. The construction of 17AH has been described previously including the characterization of multiple independently derived isolates of 17AH and its genomically restored counterpart, 17AHR. The replication of 17AH and 17AHR are equivalent in vitro and in vivo replication of 17AH and 17AHR in eyes and TG are not different (Thompson and Sawtell 1997; Thompson and Sawtell 2001). The genomic structure of 17AH and location of the latency associated riboregulators (LARRs) are shown in figure 1. The ~1.9 kb deletion in 17AH eliminates the LAT promoter and deletes exon one of the LAT primary transcript past the splice donor site utilized by the stable LAT introns (Thompson and Sawtell 1997). The deletion does not eliminate the putative promoter and AL3 ORF located on the strand opposite of LAT (Henderson, Jaber et al. 2009), but might affect the stability of this potential mRNA. No detectable LAT related RNA is expressed in neurons in vivo by this mutant (Thompson and Sawtell 1997), and the latency related microRNA miR-H6 that resides upstream of the LAT basal promoter (Umbach, Kramer et al. 2008) is also deleted as shown (fig 1).
Figure 1
Figure 1
The genomic structure of the latency associated riboregulators null mutant employed in these studies. A. A schematic of the prototypical arrangement of the HSC-1 genome is shown schematically with the unique long (UL) and unique short (US) labeled. Heavy (more ...)
Groups of outbred 5-6 week old Swiss Webster male mice were infected with 1×105 pfu of the mutant 17AH and 3×104 pfu of the genomically restored isolate 17AHR. The amount of 17AHR employed to infect the mice was adjusted so that equivalent levels of latency were obtained in both groups as previously detailed (Sawtell, Thompson et al. 2006; Thompson and Sawtell 2006; Thompson, Preston et al. 2009). The mice were maintained for 30 days post inoculation at which time the 17AH and 17AHR infected mice were each divided into two groups. One half of the latently infected mice were maintained an additional 294 days. Additional mice from these same groups were subjected to the hyperthemic stress procedure an average of 2.5 times per week during 280 days after the initial 30 day period. After week 40 the mice receiving the multiple HS treatments were rested for two weeks, and then all of the mice were subjected to a final HS procedure to induce reactivation in vivo. Two measures were employed to quantify the outcome in TG at 22 hrs post HS, (i) the quantification of infectious virus and (ii) quantification of the number of neurons exiting latency using whole ganglion immunohistochemistry (WGIHC) for viral proteins. With these methods we can reliably detect a two fold difference in the number of neurons that enter the lytic cycle or the number of TG positive and the number of pfu they contain with 95% confidence (e.g. p≤0.05 and a power of ≤0.80 as detailed previously (Thompson and Sawtell 1997; Sawtell 2003; Sawtell 2005; Sawtell, Thompson et al. 2006; Thompson, Preston et al. 2009). The results are shown in fig 2.
Figure 2
Figure 2
An intact LAT locus is associated with preservation of reactivation competent latent infections through time. Mice were infected with the LAT null mutant 17AH or the genomically restored wild type derivative 17AHR as described in the text. One half of (more ...)
In mice receiving only a single HS at 42 weeks pi, neither the frequency (% TG reactivating) nor the number of neurons exiting latency was different between mice latently infected with 17AH or 17AHR (60% and 66% of TG positive, average=3.6 and 3.7 neurons reactivating per positive TG, p=1.0) (fig.2). In the 17AHR infected mice that received either one or multiple HS treatments, no difference in either the number of neurons that exited latency, the amount of virus detected or the frequency of detection of virus was observed (p=0.9 and 0.5 respectively, Mann-Whitney test). The results with 17AHR were not different than those obtained in prior experiments with the parental strain 17Syn+ in which 68% (15/22) of latently infected mice receiving a single HS treatment were positive for reactivated virus in TG vs. 66% (14/21) of those receiving multiple HS treatments through five months were positive and the number of pfu detected in TG was also not different (p≥0.7). However, there were striking decreases in these measures in TG from mice latently infected with the LAT null virus after multiple HS treatments compared to a single treatment (fig. 2; number of neurons positive p=0.025, and number of pfu detected p=0.0007, Mann-Whitney test). Interestingly, these results indicate that the level of spontaneous reactivation in these mice was not sufficient to reduce reactivation frequency in either LAT+ or LAT null infected animals. Previous studies predict that approximately 30 single neuron reactivation events would occur spontaneously per mouse latently infected with wild type virus during this period (Sawtell 2003). The multiple HS applied through 40 weeks would be expected to induce about 300 reactivation events (including multiple neurons) with wild type virus per mouse (Sawtell 2003; Sawtell and Thompson 2004; Thompson and Sawtell 2006; Thompson, Preston et al. 2009). As noted above, the mouse infections were adjusted to generate equivalent latent infections with 17AH and 17AHR. In addition in the single HS treated groups both the LAT null and genomic rescue infected mice had the same reactivation frequency (as measured by infectious virus production), and equivalent frequency of entry into lytic protein production (measured by WGIHC). Because these frequencies are directly and highly correlated with the number of latent infections established (Sawtell 1998) there was equivalent latency was present in these groups at 42 weeks pi. Therefore these data clearly demonstrate that the LAT locus provides one or more functions that serve to maintain the frequency of reactivation following stress in the TG over time. Further, this reduced frequency of reactivation (infectious virus production) is the result of fewer neurons exiting latency (viral protein positive) which rules out the possibility that a downstream block in the replication cycle was underlying the reduced frequency of reactivation.
The above experiment revealed a previously unknown role for the LAT locus in the long term maintenance of a stable reactivation frequency. We next sought to confirm this effect of the LAT locus using an alternate strategy to reduce the time required for the experiment. We previously showed statistically significant HS induced reactivation from latency as early as 9 days pi, but the results were complicated by the presence of viral protein positive neurons in non-induced TG (Sawtell 2003). Several characteristics of in vivo infection with viruses lacking a functional thymidine kinase suggested that this background could be a suitable system to examine the role of the LAT locus early after infection. First, in the absence of TK function, HSV does not efficiently replicate in the TG, and there is no evidence of cell to cell spread of virus within the TG, consistent with the absence or extremely low levels of infectious virus recovered (Field and Wildy 1978; Tenser, Miller et al. 1979; Jacobson, Ruffner et al. 1993; Sawtell, Thompson et al. 2006). Despite this, latent infections are established and exit from latency (expression of viral proteins) can be detected following HS (Sawtell, Thompson et al. 2006; Thompson, Preston et al. 2009).
LAT null + thymidine kinase (TK) null double mutants were generated to test in the mouse model. Briefly, the TK knock out cassette we previously used to make the virus tBTK− (Pyles and Thompson 1994) was inserted into our prototypical LAT null mutant 17AH (Thompson and Sawtell 1997). In this mutation cassette a copy of the Escherichia coli LacZ gene driven by the SV40 promoter is inserted at 47563 bp in the viral genome completely eliminating TK activity while not perturbing other viral genes including UL24 (Pyles and Thompson 1994). Three independently derived dual mutants were purified to homogeneity (isolates 4-1-23, 5-2-1, and 6-9-1) as indicated by genomic structures, PCR analysis, resistance to acyclovir, and “blue plaque” assays in which ≥ 1,000 plaques were viewed for beta galactosidase (β-gal) activity (not shown).
Groups of mice were infected on scarified corneas with 1×106 pfu of either 17-AHTK− or 17LAT+TK− as detailed (Thompson and Sawtell 2001; Sawtell, Thompson et al. 2006; Thompson and Sawtell 2006). All three independent isolates displayed similar replication kinetics in vivo (not shown). These viruses achieved similar titers in the eye. However in the TG, titers of infectious virus were very low (about 3 to 4 orders of magnitude less than would be found in wild type infected TG), although levels detected in mice infected with 17AHTK− (LAT null) were greater than those detected in the 17LAT+TK− infected animals (fig 3A; isolate 4-1-23). The severe replication defect in TG is a phenotype common to most true TK null mutants (Horsburgh, Chen et al. 1998). Virus recovered from mouse TG at 4 days pi was resistant to acyclovir and retained β-gal activity. No virus was detected in any of the animals on days 6 and 8 pi (not shown). On day 9 pi the remaining mice were subjected to hyperthermic stress, which induces reactivation of HSV in vivo (Sawtell and Thompson 1992). This experiment was performed with two different 17AHTK− isolates (4-1-23 and 5-2-1) with similar results and shown are the results obtained with isolate 17AHTK− (4-1-23). Whole ganglion immunohistochemistry (WGIHC) was employed to detect neurons positive for viral proteins at 22 hours post HS as previously described (Thompson and Sawtell 1997; Sawtell 2003; Thompson, Preston et al. 2009). In the untreated group, TG neurons expressing viral proteins were not detected (0/7 and 0/10 17AHTK− and 17LAT+TK− respectively) (fig 3B). Following HS, 3/8 TG infected with the LAT+TK− mutant contained a single neuron in each of two TG and two neurons in a single TG positive for viral proteins. In contrast, 12/15 TG were positive (range= 1 to 9 positive neurons) in the LAT null TK null infected mice and this difference was significant (p=0.015 unpaired T test) (fig 3B). Thus using this experimental system, it is possible to detect a repressive effect conferred by the LAT locus on the activation of the lytic cycle in neurons as early as day 9 pi. These findings are consistent with the function of this locus in enhancing the number of latent infections (Sawtell and Thompson 1992; Thompson and Sawtell 1997; Perng, Slanina et al. 2000; Thompson and Sawtell 2001). However, whether this represents a single or multiple mechanisms is not known.
Figure 3
Figure 3
In mice infected with a LAT deletion mutant the permisivity of trigeminal neurons is increased. A. Mice were infected via scarified corneas with 1×106 pfu of 17LAT+TK− or 17AHTK− (LAT null and TK null). B. Groups of mice were maintained (more ...)
How the LAT locus accomplishes this task is also not yet known. It has been known for nearly two decades that the LAT locus exerts a negative influence on lytic viral gene expression (Sawtell and Thompson 1992; Garber, Schaffer et al. 1997; Thompson and Sawtell 1997; Thompson and Sawtell 2001). Some groups suggest that viral proteins are expressed during latency, but their functions are not known (Green, Courtney et al. 1981; Doerig, Pizer et al. 1991; Thomas, Gough et al. 1999; Perng, Maguen et al. 2002; Thomas, Lilley et al. 2002; Henderson, Jaber et al. 2009; Jaber, Henderson et al. 2009). It has been suggested that the stable 2kb and 1.5 kb LAT introns might serve as a natural anti-sense RNA mechanism to inhibit the production the immediate early (IE) transactivation protein ICP0 (Stevens, Wagner et al. 1987), this has been demonstrated in transient assays (Farrell, Dobson et al. 1991), and may account for our observation of a post transcriptional constraint on ICP0 production mediated by the LAT locus during reactivation from latency (Thompson, Shieh et al. 2003). It is also possible that miR-H2 inhibits ICP0 expression (Umbach, Kramer et al. 2008), although that remains to be demonstrated. Silencing RNAs based on the sequence of miR-H6 have been shown to inhibit the production of the IE transactivator protein ICP4 in transfection studies (Umbach, Kramer et al. 2008), but we have not been able to detect silencing activity of miR-H6 expressed in an inducible cell line on luciferase gene targets containing the putative miR-H6 binding site (data not shown). Still, this microRNA, or others encoded in the LAT locus and expressed during latency may regulate viral and/or host protein expression in as yet unknown ways to modulate reactivation frequency.
Contributor Information
Richard L. Thompson, Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, 45267-0524, USA.
Nancy M. Sawtell, Department of Pediatrics, Division of Infectious Diseases, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio 45229-3039.
  • Arthur J, Efstathiou S, et al. Intranuclear foci containing low abundance herpes simplex virus latency-associated transcripts visualized by non-isotopic in situ hybridization. J Gen Virol. 1993;74(Pt 7):1363–70. [PubMed]
  • Bloom DC, Devi-Rao GB, et al. Molecular analysis of herpes simplex virus type 1 during epinephrine- induced reactivation of latently infected rabbits in vivo. J Virol. 1994;68(3):1283–92. [PMC free article] [PubMed]
  • Deatly AM, Spivack JG, et al. RNA from an immediate early region of the type 1 herpes simplex virus genome is present in the trigeminal ganglia of latently infected mice. Proc Natl Acad Sci U S A. 1987;84(10):3204–8. [PubMed]
  • Doerig C, Pizer LI, et al. An antigen encoded by the latency-associated transcript in neuronal cell cultures latently infected with herpes simplex virus type 1. J Virol. 1991;65(5):2724–7. [PMC free article] [PubMed]
  • Farrell MJ, Dobson AT, et al. Herpes simplex virus latency-associated transcript is a stable intron. Proc Natl Acad Sci U S A. 1991;88(3):790–4. [PubMed]
  • Field HJ, Wildy P. The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. J Hyg (Lond) 1978;81(2):267–77. [PMC free article] [PubMed]
  • Fuchs J, Celum C, et al. Clinical and Virologic Efficacy of Herpes Simplex Virus Type 2 Suppression by Acyclovir in a Multicontinent Clinical Trial. J Infect Dis. 2010 [PMC free article] [PubMed]
  • Garber DA, Schaffer PA, et al. A LAT-associated function reduces productive-cycle gene expression during acute infection of murine sensory neurons with herpes simplex virus type 1. J Virol. 1997;71(8):5885–93. [PMC free article] [PubMed]
  • Glynn JR, Biraro S, et al. Herpes simplex virus type 2: a key role in HIV incidence. Aids. 2009;23(12):1595–8. [PubMed]
  • Green MT, Courtney RJ, et al. Detection of an immediate early herpes simplex virus type 1 polypeptide in trigeminal ganglia from latently infected animals. Infect Immun. 1981;34(3):987–92. [PMC free article] [PubMed]
  • Henderson G, Jaber T, et al. Identification of herpes simplex virus type 1 proteins encoded within the first 1.5 kb of the latency-associated transcript. J Neurovirol. 2009;15(5-6):439–48. [PubMed]
  • Horsburgh BC, Chen SH, et al. Recurrent acyclovir-resistant herpes simplex in an immunocompromised patient: can strain differences compensate for loss of thymidine kinase in pathogenesis? J Infect Dis. 1998;178(3):618–25. [PubMed]
  • Jaber T, Henderson G, et al. Identification of a novel herpes simplex virus type 1 transcript and protein (AL3) expressed during latency. J Gen Virol. 2009;90(Pt 10):2342–52. [PMC free article] [PubMed]
  • Jacobson JG, Ruffner KL, et al. Herpes simplex virus thymidine kinase and specific stages of latency in murine trigeminal ganglia. J Virol. 1993;67(11):6903–8. [PMC free article] [PubMed]
  • Kang W, Mukerjee R, et al. Establishment and maintenance of HSV latent infection is mediated through correct splicing of the LAT primary transcript. Virology. 2003;312(1):233–44. [PubMed]
  • Peng W, Vitvitskaia O, et al. Identification of two small RNAs within the first 1.5-kb of the herpes simplex virus type 1-encoded latency-associated transcript. J Neurovirol. 2008;14(1):41–52. [PubMed]
  • Pepose JS, Keadle TL, et al. Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy. Am J Ophthalmol. 2006;141(3):547–557. [PubMed]
  • Perng GC, Dunkel EC, et al. The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency. J Virol. 1994;68(12):8045–55. [PMC free article] [PubMed]
  • Perng GC, Maguen B, et al. A novel herpes simplex virus type 1 transcript (AL-RNA) antisense to the 5′ end of the latency-associated transcript produces a protein in infected rabbits. J Virol. 2002;76(16):8003–10. [PMC free article] [PubMed]
  • Perng GC, Slanina SM, et al. The latency-associated transcript gene enhances establishment of herpes simplex virus type 1 latency in rabbits. J Virol. 2000;74(4):1885–91. [PMC free article] [PubMed]
  • Pyles RB, Thompson RL. Mutations in accessory DNA replicating functions alter the relative mutation frequency of herpes simplex virus type 1 strains in cultured murine cells. J Virol. 1994;68(7):4514–24. [PMC free article] [PubMed]
  • Rock DL, Nesburn AB, et al. Detection of latency-related viral RNAs in trigeminal ganglia of rabbits latently infected with herpes simplex virus type 1. J Virol. 1987;61(12):3820–6. [PMC free article] [PubMed]
  • Roizman B, Knipe DM, Whitley RJ. Herpes Simplex Viruses. In: Knipe D, Howley P, editors. Fields Virology. Lippincott Williams & Wilkins; Philadelphia: 2007. pp. 2501–2602.
  • Sawtell NM. Comprehensive quantification of herpes simplex virus latency at the single-cell level. J Virol. 1997;71(7):5423–31. [PMC free article] [PubMed]
  • Sawtell NM. The probability of in vivo reactivation of herpes simplex virus type 1 increases with the number of latently infected neurons in the ganglia. J Virol. 1998;72(8):6888–92. [PMC free article] [PubMed]
  • Sawtell NM. Quantitative Analysis of Herpes Simplex Virus Reactivation In Vivo Demonstrates that Reactivation in the Nervous System Is Not Inhibited at Early Times Postinoculation. J Virol. 2003;77(7):4127–38. [PMC free article] [PubMed]
  • Sawtell NM. Detection and quantification of the rare latently infected cell undergoing herpes simplex virus transcriptional activation in the nervous system in vivo. Methods Mol Biol. 2005;292:57–72. [PubMed]
  • Sawtell NM, Poon DK, et al. The latent herpes simplex virus type 1 genome copy number in individual neurons is virus strain specific and correlates with reactivation. J Virol. 1998;72(7):5343–50. [PMC free article] [PubMed]
  • Sawtell NM, Thompson RL. Herpes simplex virus type 1 latency-associated transcription unit promotes anatomical site-dependent establishment and reactivation from latency. J Virol. 1992;66(4):2157–69. [PMC free article] [PubMed]
  • Sawtell NM, Thompson RL. Rapid in vivo reactivation of herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia. J Virol. 1992;66(4):2150–6. [PMC free article] [PubMed]
  • Sawtell NM, Thompson RL. Comparison of herpes simplex virus reactivation in ganglia in vivo and in explants demonstrates quantitative and qualitative differences. J Virol. 2004;78(14):7784–94. [PMC free article] [PubMed]
  • Sawtell NM, Thompson RL, et al. Herpes simplex virus DNA synthesis is not a decisive regulatory event in the initiation of lytic viral protein expression in neurons in vivo during primary infection or reactivation from latency. J Virol. 2006;80(1):38–50. [PMC free article] [PubMed]
  • Sedarati F, Izumi KM, et al. Herpes simplex virus type 1 latency-associated transcription plays no role in establishment or maintenance of a latent infection in murine sensory neurons. J Virol. 1989;63(10):4455–8. [PMC free article] [PubMed]
  • Stevens JG, Wagner EK, et al. RNA complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons. Science. 1987;235(4792):1056–9. [PubMed]
  • Stone MJ, Hawkins CP. A medical overview of encephalitis. Neuropsychol Rehabil. 2007;17(4-5):429–49. [PubMed]
  • Tenser RB, Miller RL, et al. Trigeminal ganglion infection by thymidine kinase-negative mutants of herpes simplex virus. Science. 1979;205(4409):915–7. [PubMed]
  • Thomas SK, Gough G, et al. Herpes simplex virus latency-associated transcript encodes a protein which greatly enhances virus growth, can compensate for deficiencies in immediate-early gene expression, and is likely to function during reactivation from virus latency. J Virol. 1999;73(8):6618–25. [PMC free article] [PubMed]
  • Thomas SK, Lilley CE, et al. A protein encoded by the herpes simplex virus (HSV) type 1 2-kilobase latency-associated transcript is phosphorylated, localized to the nucleus, and overcomes the repression of expression from exogenous promoters when inserted into the quiescent HSV genome. J Virol. 2002;76(8):4056–67. [PMC free article] [PubMed]
  • Thompson RL, Preston CM, et al. De novo synthesis of VP16 coordinates the exit from HSV latency in vivo. PLoS Pathog. 2009;5(3):e1000352. [PMC free article] [PubMed]
  • Thompson RL, Sawtell NM. The herpes simplex virus type 1 latency-associated transcript gene regulates the establishment of latency. J Virol. 1997;71(7):5432–40. [PMC free article] [PubMed]
  • Thompson RL, Sawtell NM. Herpes simplex virus type 1 latency-associated transcript gene promotes neuronal survival. J Virol. 2001;75(14):6660–75. [PMC free article] [PubMed]
  • Thompson RL, Sawtell NM. Evidence that the herpes simplex virus type 1 ICP0 protein does not initiate reactivation from latency in vivo. J Virol. 2006;80(22):10919–30. [PMC free article] [PubMed]
  • Thompson RL, Shieh MT, et al. Analysis of herpes simplex virus ICP0 promoter function in sensory neurons during acute infection, establishment of latency, and reactivation in vivo. J Virol. 2003;77(22):12319–30. [PMC free article] [PubMed]
  • Toma HS, Murina AT, et al. Ocular HSV-1 latency, reactivation and recurrent disease. Semin Ophthalmol. 2008;23(4):249–73. [PubMed]
  • Umbach JL, Kramer MF, et al. MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. Nature. 2008;454(7205):780–3. [PMC free article] [PubMed]
  • Wechsler SL, Nesburn AB, et al. Fine mapping of the latency-related gene of herpes simplex virus type 1: alternative splicing produces distinct latency-related RNAs containing open reading frames. J Virol. 1988;62(11):4051–8. [PMC free article] [PubMed]